Matches in SemOpenAlex for { <https://semopenalex.org/work/W2944626625> ?p ?o ?g. }
- W2944626625 endingPage "1398" @default.
- W2944626625 startingPage "1385" @default.
- W2944626625 abstract "PurposeTo elucidate the clinical and epidemiologic characteristics of optic neuritis in Japan.DesignMulticenter cross-sectional, observational cohort study.ParticipantsA total of 531 cases of unilateral or bilateral noninfectious optic neuritis identified in 33 institutions nationwide in Japan.MethodsSerum samples from patients with optic neuritis were tested for anti–aquaporin-4 antibodies (AQP4-Abs) and anti–myelin oligodendrocyte glycoprotein antibodies (MOG-Abs) using a cell-based assay and were correlated with the clinical findings.Main Outcome MeasuresAntibody positivity, clinical and radiologic characteristics, and visual outcome.ResultsAmong 531 cases of optic neuritis, 12% were AQP4-Ab positive, 10% were MOG-Ab positive, 77% were negative for both antibodies (double-negative), and 1 case was positive for both antibodies. Pretreatment visual acuity (VA) worsened to more than a median 1.0 logarithm of the minimum angle of resolution (logMAR) in all groups. After steroid pulse therapy (combined with plasmapheresis in 32% of patients in AQP4-Ab–positive group), median VA improved to 0.4 logMAR in the AQP4-Ab–positive group, 0 logMAR in the MOG-Ab–positive group, and 0.1 logMAR in the double-negative group. The AQP4-Ab–positive group showed a high proportion of females, exhibited diverse visual field abnormalities, and demonstrated concurrent spinal cord lesions on magnetic resonance imaging (MRI) in 22% of the patients. In the MOG-Ab–positive group, although posttreatment visual outcome was good, the rates of optic disc swelling and pain with eye movement were significantly higher than those in the AQP4-Ab–positive and double-negative groups. However, most cases showed isolated optic neuritis lesions on MRI. In the double-negative group, 4% of the patients had multiple sclerosis. Multivariate logistic regression analysis of all participants identified age and presence of antibodies (MOG-Ab and AQP4-Ab) as significant factors affecting visual outcome.ConclusionsThe present large-scale cohort study revealed the clinicoepidemiologic features of noninfectious optic neuritis in Japan. Anti–aquaporin-4 antibody–positive optic neuritis has poor visual outcome. In contrast, MOG-Ab positive cases manifested severe clinical findings of optic neuritis before treatment, but few showed concurrent lesions in sites other than the optic nerve and generally showed good treatment response with favorable visual outcome. These findings indicate that autoantibody measurement is useful for prompt diagnosis and proper management of optic neuritis that tends to become refractory. To elucidate the clinical and epidemiologic characteristics of optic neuritis in Japan. Multicenter cross-sectional, observational cohort study. A total of 531 cases of unilateral or bilateral noninfectious optic neuritis identified in 33 institutions nationwide in Japan. Serum samples from patients with optic neuritis were tested for anti–aquaporin-4 antibodies (AQP4-Abs) and anti–myelin oligodendrocyte glycoprotein antibodies (MOG-Abs) using a cell-based assay and were correlated with the clinical findings. Antibody positivity, clinical and radiologic characteristics, and visual outcome. Among 531 cases of optic neuritis, 12% were AQP4-Ab positive, 10% were MOG-Ab positive, 77% were negative for both antibodies (double-negative), and 1 case was positive for both antibodies. Pretreatment visual acuity (VA) worsened to more than a median 1.0 logarithm of the minimum angle of resolution (logMAR) in all groups. After steroid pulse therapy (combined with plasmapheresis in 32% of patients in AQP4-Ab–positive group), median VA improved to 0.4 logMAR in the AQP4-Ab–positive group, 0 logMAR in the MOG-Ab–positive group, and 0.1 logMAR in the double-negative group. The AQP4-Ab–positive group showed a high proportion of females, exhibited diverse visual field abnormalities, and demonstrated concurrent spinal cord lesions on magnetic resonance imaging (MRI) in 22% of the patients. In the MOG-Ab–positive group, although posttreatment visual outcome was good, the rates of optic disc swelling and pain with eye movement were significantly higher than those in the AQP4-Ab–positive and double-negative groups. However, most cases showed isolated optic neuritis lesions on MRI. In the double-negative group, 4% of the patients had multiple sclerosis. Multivariate logistic regression analysis of all participants identified age and presence of antibodies (MOG-Ab and AQP4-Ab) as significant factors affecting visual outcome. The present large-scale cohort study revealed the clinicoepidemiologic features of noninfectious optic neuritis in Japan. Anti–aquaporin-4 antibody–positive optic neuritis has poor visual outcome. In contrast, MOG-Ab positive cases manifested severe clinical findings of optic neuritis before treatment, but few showed concurrent lesions in sites other than the optic nerve and generally showed good treatment response with favorable visual outcome. These findings indicate that autoantibody measurement is useful for prompt diagnosis and proper management of optic neuritis that tends to become refractory." @default.
- W2944626625 created "2019-05-16" @default.
- W2944626625 creator A5000369726 @default.
- W2944626625 creator A5000732041 @default.
- W2944626625 creator A5010414704 @default.
- W2944626625 creator A5010652134 @default.
- W2944626625 creator A5012614932 @default.
- W2944626625 creator A5013007335 @default.
- W2944626625 creator A5021280124 @default.
- W2944626625 creator A5021522402 @default.
- W2944626625 creator A5024445333 @default.
- W2944626625 creator A5024752284 @default.
- W2944626625 creator A5030187777 @default.
- W2944626625 creator A5031156655 @default.
- W2944626625 creator A5031377508 @default.
- W2944626625 creator A5042071045 @default.
- W2944626625 creator A5042832298 @default.
- W2944626625 creator A5042992987 @default.
- W2944626625 creator A5045478397 @default.
- W2944626625 creator A5047388069 @default.
- W2944626625 creator A5048008812 @default.
- W2944626625 creator A5049584975 @default.
- W2944626625 creator A5050156974 @default.
- W2944626625 creator A5055929283 @default.
- W2944626625 creator A5059210675 @default.
- W2944626625 creator A5059801301 @default.
- W2944626625 creator A5064465850 @default.
- W2944626625 creator A5065176106 @default.
- W2944626625 creator A5066766955 @default.
- W2944626625 creator A5067338493 @default.
- W2944626625 creator A5069375075 @default.
- W2944626625 creator A5071644916 @default.
- W2944626625 creator A5072957496 @default.
- W2944626625 creator A5073983628 @default.
- W2944626625 creator A5077906724 @default.
- W2944626625 creator A5081871887 @default.
- W2944626625 creator A5083609672 @default.
- W2944626625 creator A5086045743 @default.
- W2944626625 date "2019-10-01" @default.
- W2944626625 modified "2023-10-16" @default.
- W2944626625 title "Epidemiologic and Clinical Characteristics of Optic Neuritis in Japan" @default.
- W2944626625 cites W110902629 @default.
- W2944626625 cites W1485066308 @default.
- W2944626625 cites W1524145136 @default.
- W2944626625 cites W1764508635 @default.
- W2944626625 cites W1878669653 @default.
- W2944626625 cites W1968966789 @default.
- W2944626625 cites W1993761012 @default.
- W2944626625 cites W2007502293 @default.
- W2944626625 cites W2008299268 @default.
- W2944626625 cites W2021835807 @default.
- W2944626625 cites W2024946073 @default.
- W2944626625 cites W2025466202 @default.
- W2944626625 cites W2047681411 @default.
- W2944626625 cites W2070855278 @default.
- W2944626625 cites W2076901976 @default.
- W2944626625 cites W2088811334 @default.
- W2944626625 cites W2103812851 @default.
- W2944626625 cites W2108526545 @default.
- W2944626625 cites W2114414511 @default.
- W2944626625 cites W2114516570 @default.
- W2944626625 cites W2120238028 @default.
- W2944626625 cites W2122545833 @default.
- W2944626625 cites W2129404804 @default.
- W2944626625 cites W2130830366 @default.
- W2944626625 cites W2169522944 @default.
- W2944626625 cites W2171753008 @default.
- W2944626625 cites W2190449607 @default.
- W2944626625 cites W2206286096 @default.
- W2944626625 cites W2268470155 @default.
- W2944626625 cites W2321839851 @default.
- W2944626625 cites W2479922137 @default.
- W2944626625 cites W2520070923 @default.
- W2944626625 cites W2542372902 @default.
- W2944626625 cites W2761202816 @default.
- W2944626625 cites W2784830850 @default.
- W2944626625 cites W2793299920 @default.
- W2944626625 cites W2795024322 @default.
- W2944626625 cites W2800470167 @default.
- W2944626625 cites W2803257223 @default.
- W2944626625 cites W2883344170 @default.
- W2944626625 cites W2890082735 @default.
- W2944626625 cites W2893913323 @default.
- W2944626625 cites W2898553481 @default.
- W2944626625 cites W4248649229 @default.
- W2944626625 cites W4252126246 @default.
- W2944626625 doi "https://doi.org/10.1016/j.ophtha.2019.04.042" @default.
- W2944626625 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31196727" @default.
- W2944626625 hasPublicationYear "2019" @default.
- W2944626625 type Work @default.
- W2944626625 sameAs 2944626625 @default.
- W2944626625 citedByCount "65" @default.
- W2944626625 countsByYear W29446266252019 @default.
- W2944626625 countsByYear W29446266252020 @default.
- W2944626625 countsByYear W29446266252021 @default.
- W2944626625 countsByYear W29446266252022 @default.
- W2944626625 countsByYear W29446266252023 @default.
- W2944626625 crossrefType "journal-article" @default.